This post was originally published on this site Cumulative evidence to date supports the implementation of stereotactic body radiotherapy — a highly precise radiation therapy delivered in shorter periods of time — as a standard treatment for people with localized prostate cancer, a study shows. The study, “Stereotactic Body Radiotherapy for Localized Prostate Cancer: A…
Conditions
Conditions
Here I Am
This post was originally published on this site I remember when my daughter performed at a talent show at her school. I’d just had my fourth round of chemotherapy, and my condition was critical. For me, every chemo session had its own little life cycle, each with a unique set of challenges and logistics. Because…
$4.6M CIRM Grant to Fund Phase 1 Trial of New Immunotherapy for Advanced Sarcoma, Difficult-to-Treat Cancers
This post was originally published on this site The California Institute for Regenerative Medicine (CIRM) has awarded a $4.6 million grant to researchers at the UCLA Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research for an ongoing Phase 1 clinical trial testing a new immunotherapy for advanced sarcoma and other hard-to-treat cancers.…
Health Canada Approves Adcetris-Chemo for Advanced Classical Hodgkin’s Lymphoma
This post was originally published on this site Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s lymphoma. This approval — which makes the regimen accessible to physicians and eligible patients in Canada — was…
Sleep Molecules May Represent a New Blood Biomarker for Earlier Diagnosis, Study Suggests
This post was originally published on this site High blood levels of primary fatty acid amides (PFAMS), a class of fatty molecules involved in sleep and movement control, are associated with increased accumulation of beta-amyloid protein in the cerebrospinal fluid of patients with Alzheimer’s disease, a study finds. Researchers believe that this class of fatty…
Experimental Antibody Therapy Leads to Significant Responses in HER2-positive Breast Cancer, Phase 2 Trial Shows
This post was originally published on this site Trastuzumab deruxtecan (DS-8201), an investigational antibody-drug conjugate developed by AstraZeneca with Daiicho Sankyo, led to clinically meaningful responses in patients with advanced HER2-positive breast cancer, a Phase 2 clinical trial shows. Trastuzumab deruxtecan is a combination of the anti-cancer HER2-targeting antibody trastuzumab (marketed under the brand name Herceptin), and an…
Rare Diseases Constitute a ‘Public Health Issue,’ NCATS Director Warns
This post was originally published on this site With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies(NCATS)…
Takeda Oncology Launches Myeloma Patient and Caregiver Mentorship Support Program
This post was originally published on this site Takeda Oncology has launched a mentorship program aimed at empowering and encouraging multiple myeloma patients and caregivers throughout their disease journey. Called My Mentor Connections, the program enlists caregivers and patients as mentors who volunteer to provide answers and support over the phone to other patients or…
Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests
This post was originally published on this site Treating chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients with Xtandi (enzalutamide) leads to better survival outcomes and lower healthcare costs than Zytiga (abiraterone acetate), a study suggests. The findings were presented at the American Urological Association’s 2019 Annual Meeting, May 3-6, in Chicago, in the study, “Survival…
2 Planned Clinical Trials to Test Ways of Preventing Alzheimer’s at Early Stages
This post was originally published on this site Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of Alzheimer’s disease. ACTC is a network of 35 primary clinical trial sites across the U.S., established by the…
First Patients Dosed in iTeos’ Experimental A2A Receptor Antagonist Trial for Solid Tumors
This post was originally published on this site iTeos Therapeutics’ Phase 1/1b clinical trial testing its experimental A2A receptor antagonist, EOS100850, has dosed the first group of patients with advanced solid tumors, the company announced. “I am tremendously excited to announce that patient dosing in our innovative, adaptive Phase 1/1b trial is now underway with…
FDA Approves Venclexta-Gazyva Combo for Untreated CLL/SLL Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has approved the double combination therapy of Venclexta (venetoclax) and Gazyva (obinutuzumab) for the treatment of adults with newly diagnosed chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venclexta is a potent selective inhibitor of the B-cell lymphoma-2 (BCL-2)…